Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...

The widely used anti-diabetes and weight loss drug Mounjaro, which contains the active ingredient tirzepatide, is now ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India. Here's what ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

Despite the promising results, further research is needed before GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists can be integrated into standard T1D treatment.

Depending on dosage, a patient may spend ... and metabolic benefits due to its dual action. This makes it more effective for weight loss compared to Ozempic. Comparing their effectiveness Mounjaro ...